Company has submitted Integrated (Financials) for the Half year and year ended on March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.9 pts more than Nifty Microcap 250 and 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Trident Lifeline Ltd has submitted its audited financial results for FY 2024-25 along with the Integrated Filing. On a standalone basis, total income grew strongly to Rs. 70.94 crore from Rs. 46.86 crore in FY 2023-24 (about 51% jump), while net profit rose modestly to Rs. 7.04 crore from Rs. 6.34 crore (about 11%). EPS stood at Rs. 6.23 vs Rs. 5.52 earlier. On a consolidated basis, which now includes five newly acquired subsidiaries (TNS Pharma, TLL Parenterals, TLL Herbal, TLL Elements, and Trident Mediquip), total income jumped to Rs. 95.68 crore but net profit came in slightly lower at Rs. 5.94 crore vs Rs. 6.34 crore standalone last year, reflecting consolidation and acquisition costs. The statutory auditor (A Bafna & Associates) issued an unmodified opinion, and DAC & Co. was appointed as the new Internal Auditor for FY 2025-26. The IPO proceeds of Rs. 35.34 crore (raised in October 2022) have been substantially utilized (Rs. 30.27 crore) with no deviations reported.
Strong topline growth driven mainly by consolidation of new subsidiaries, while bottom-line growth on a standalone basis remains modest and consolidated profit dipped slightly, which investors should weigh. Clean audit report and orderly IPO fund usage are positive governance signals for shareholders.